Shaaban HE, Abdellatef A, Okasha HH. Hepatic recompensation according to Baveno VII criteria via transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2024; 30(12): 1777-1779 [PMID: 38617737 DOI: 10.3748/wjg.v30.i12.1777]
Corresponding Author of This Article
Hossam Eldin Shaaban, FACG, FASGE, MD, MSc, PhD, Doctor, Department of Internal Medicine and Gastroenterology, NHTMRI, No. 10 Kasr Alainy Street, Cairo 11796, Egypt. hsshaaban@aol.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Shaaban HE, Abdellatef A, Okasha HH. Hepatic recompensation according to Baveno VII criteria via transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2024; 30(12): 1777-1779 [PMID: 38617737 DOI: 10.3748/wjg.v30.i12.1777]
Hossam Eldin Shaaban, Department of Internal Medicine and Gastroenterology, NHTMRI, Cairo 11796, Egypt
Abeer Abdellatef, Hussein Hassan Okasha, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kasr Al-Aini School of Medicine, Cairo University, Cairo 11562, Egypt
Author contributions: Shaaban HE, Abdellatef A, and Okasha HH, shared equally in letter writing; Okasha HH revised the letter.
Conflict-of-interest statement: The authors have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hossam Eldin Shaaban, FACG, FASGE, MD, MSc, PhD, Doctor, Department of Internal Medicine and Gastroenterology, NHTMRI, No. 10 Kasr Alainy Street, Cairo 11796, Egypt. hsshaaban@aol.com
Received: October 29, 2023 Peer-review started: October 29, 2023 First decision: December 6, 2023 Revised: December 30, 2023 Accepted: February 20, 2024 Article in press: February 20, 2024 Published online: March 28, 2024 Processing time: 150 Days and 22.7 Hours
Abstract
Transjugular intrahepatic portosystemic shunt is a therapeutic modality done through interventional radiology. It is aimed to decrease portal pressure in special situations for patients with decompensated liver disease with portal hypertension. It represents a potential addition to the therapeutic modalities that could achieve hepatic recompensation in those patients based on Baveno VII criteria.
Core Tip: Liver cirrhosis is a complication of chronic liver disease. Hepatic decompensation follows a period of compensation if the etiology of the chronic liver disease is not eliminated and the liver inflammation is persistent. Hepatic recompensation is a novel term in which decompensation reverses after the clearance of the etiological factors in some patients. The use of a transjugular intrahepatic portosystemic shunt is a potential addition to achieve recompensation in a subset of patients with portal hypertension as demonstrated in published research.